Fluorescein isothiocyanate epitope (FITC epitope)

The Fluorescein isothiocyanate (FITC) epitope on FITC-labeled adapter molecules is a synthetic target utilized in advanced 'universal' or 'switchable' chimeric antigen receptor (CAR) T-cell therapies. In this therapeutic paradigm, the FITC molecule functions as a hapten conjugated to a targeting ligand (the adapter) that specifically homes to tumor-associated antigens such as Folate Receptor or PSMA (Lee et al., 2019). The primary therapeutic agent, typically an anti-FITC CAR-T cell, is engineered to recognize the FITC moiety rather than the tumor antigen itself. This modular approach allows for precise control over T-cell activity by adjusting the administration and dosage of the adapter molecule, which can help mitigate severe side effects like cytokine release syndrome (Kim et al., 2015). Furthermore, this system enables a single CAR-T cell product to be redirected against various tumor types simply by swapping the FITC-labeled adapter molecule (Ma et al., 2016).

Other names

FITC haptenFluorescein isothiocyanateFITC-labeled adapter targetFluorescein epitope

The FITC epitope acts as a bridge in a binary therapeutic system. A FITC-labeled adapter molecule (bispecific) binds to a tumor-associated antigen (TAA) via a targeting ligand. Subsequently, an anti-FITC therapeutic agent, such as a CAR-T cell or antibody, recognizes and binds to the FITC epitope displayed on the tumor cell surface, leading to localized immune activation and tumor cell lysis (Ma et al., 2016; Kim et al., 2015).